Eiger BioPharmaceuticals (NASDAQ:EIGR) reported its Q1 earnings results on Thursday, May 11, 2023 at 04:00 PM.
Here’s what investors need to know about the announcement.
Earnings
Eiger BioPharmaceuticals missed estimated earnings by 10.64%, reporting an EPS of $-0.52 versus an estimate of $-0.47.
Revenue was up $1.45 million from the same period last year.
Past Earnings Performance
Last quarter the company missed on EPS by $0.03 which was followed by a 5.56% drop in the share price the next day.
Here’s a look at Eiger BioPharmaceuticals’s past performance:
| Quarter | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 |
|---|---|---|---|---|
| EPS Estimate | -0.54 | -0.52 | -0.61 | -0.64 |
| EPS Actual | -0.57 | -0.62 | -0.51 | -0.64 |
| Revenue Estimate | 4.43M | 4.27M | 4.68M | 4.04M |
| Revenue Actual | 2.70M | 4.02M | 4.09M | 2.67M |
To track all earnings releases for Eiger BioPharmaceuticals visit their earnings calendar here.
This article was generated by Benzinga’s automated content engine and reviewed by an editor.
